How to Reconstitute & Measure a Compounded GLP-1 Microdose

Search for how to reconstitute a compounded GLP-1 and you'll find step-by-step videos and forum walkthroughs that make it look like a tidy kitchen recipe: add water, swirl, draw up, inject. The arithmetic itself is simple — it's grade-school dilution math. But the practice sits on top of something the tutorials usually skip past: the product is a grey-market compounded preparation, the math has a single step where a tenfold slip turns a "microdose" into a large overdose, and the whole regimen has never been tested in a clinical trial. This page explains the reconstitution math plainly so you can understand what these tutorials are actually asking you to do — and is honest about where the real danger lives. It is a description of a risky off-label practice, not instructions to do it, and not medical advice.

Why this is reconstitution in the first place

A quick orientation, because it explains the whole risk profile. Branded GLP-1 drugs — Wegovy, Ozempic, Zepbound, Mounjaro — come pre-mixed in fixed-dose pens. You can't easily take a custom sub-dose from them, which is why people who want to "microdose" almost always turn to a compounded vial instead. Compounded GLP-1 frequently ships as a lyophilized (freeze-dried) powder that the user has to rehydrate — "reconstitute" — with bacteriostatic water before it can be drawn into a syringe. That handoff of preparation from a regulated manufacturer to the end user is the source of nearly every microdosing-specific hazard, and it's why the clinical literature on microdosing is cautionary rather than reassuring: it warns specifically about dosing errors, pen and vial manipulation, medication sharing, and unregulated sourcing¹.

The reconstitution math, step by step

The math is arithmetic, not pharmacology — it's a concentration calculation, the same one a chemistry class would call molarity in different units. There are three numbers and they're locked together:

1. Total drug in the vial (mg). This is whatever the compounding pharmacy put in — say a vial labeled "10 mg." You have to trust the label here, which is exactly the problem we'll come back to.

2. Volume of bacteriostatic water you add (mL). This is your choice, and it sets the concentration. Add 1 mL to a 10 mg vial and you get 10 mg/mL. Add 2 mL to the same vial and you get 5 mg/mL. The drug amount didn't change — you just spread it through more or less water.

3. Concentration (mg/mL) = total mg ÷ mL added. That's the whole formula. A 10 mg vial reconstituted with 2 mL of water is 5 mg/mL.

To find how much liquid contains your target dose, you flip it around: volume to draw (mL) = target dose (mg) ÷ concentration (mg/mL). If you wanted a 1 mg dose from that 5 mg/mL vial, you'd draw 1 ÷ 5 = 0.2 mL.

So far, so simple. The trap is the next step.

The dangerous step: converting mL to "units"

Almost nobody measures GLP-1 in milliliters at the syringe, because the syringes people use are U-100 insulin syringes marked in "units," not mL. On a U-100 syringe, 100 units = 1 mL, so 1 unit = 0.01 mL. To turn your drawn volume into units you multiply by 100.

Carrying the example forward: 0.2 mL × 100 = 20 units on the insulin syringe for a 1 mg dose from a 5 mg/mL vial.

Here is the entire problem with reconstitution microdosing in one sentence: that "20 units" answer is only correct for that exact vial at that exact concentration. Reconstitute the same 10 mg vial with 1 mL instead of 2 mL and it becomes 10 mg/mL, so the same 20 units now delivers 2 mg, not 1 mg — double the intended dose. Get the vial's true milligram content wrong, or misremember how much water you added, and the error rides straight through to your body. A chart or video that says "draw 20 units" without pinning down the concentration is not just unhelpful — it's actively dangerous, because the same number of units can mean wildly different doses.

This is why the clinical caution about microdosing centers on measurement and preparation, not the milligram goal itself. The number on the syringe barrel is meaningless until the concentration is known and verified — and verifying it depends on trusting a compounded label that pharmacovigilance data suggest you can't always trust.

Why "trust the label" is the weak link

Reconstitution math assumes the vial contains exactly what the label says. With compounded product, that assumption carries documented risk. A pharmacovigilance analysis of compounded GLP-1 receptor agonists using the FDA Adverse Event Reporting System found sharply elevated reporting odds for preparation errors (reporting odds ratio about 48.9), contamination (about 19.0), compounding issues (about 8.5), and prescribing errors (about 4.5), along with more reports of abdominal pain, cholecystitis, and hospitalization². Those are association signals from a voluntary reporting database, not proof of causation — but they land exactly where the math is most fragile: if the true milligram content differs from the label, every downstream calculation is wrong by the same factor, no matter how carefully you do the arithmetic. We go deeper on this in is compounded / microdosed GLP-1 safe.

There's also a sterility dimension the word "bacteriostatic" is doing a lot of work to cover. Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacterial growth in a multi-use vial — it does not sterilize a contaminated preparation, and it isn't a license to be casual about clean technique, repeated needle entries, or storage. Contamination was the second-highest signal in that pharmacovigilance analysis², and GLP-1 drugs already carry gastrointestinal risks — a large real-world analysis linked GLP-1 receptor agonists used for weight loss to elevated risk of pancreatitis, bowel obstruction, and gastroparesis³ — so an injection-site or systemic infection stacks on top of risks that don't disappear at a low dose.

Even if the math is perfect, the dose may be too low to matter

Suppose every number is right and the technique is clean. The reconstitution still doesn't answer the question that matters most: does a sub-starter dose actually do anything? The dose-finding evidence says less drug does less. In a phase 2 dose-ranging trial of semaglutide for weight loss, mean weight loss scaled cleanly with dose — roughly 6% at 0.05 mg up to about 13.8% at 0.4 mg⁴. Tirzepatide shows the same gradient in SURMOUNT-1, where higher tiers produced more weight loss⁵. A microdose sits at the very bottom of that curve. And the benefit depends on adequate ongoing exposure: in STEP 4, people who stopped semaglutide regained weight while those who continued held their loss⁶. A dose low enough to call a "microdose" may simply be too small to reach or hold a meaningful effect. We lay the numbers out in GLP-1 dose-response: why lower doses do less and our pillar, what the microdosing evidence actually says.

The honest bottom line

The reconstitution arithmetic is genuinely simple — concentration equals milligrams divided by milliliters, and units equal milliliters times 100. What's not simple, and not safe, is everything the arithmetic rests on: a compounded label you have to trust, a concentration you set yourself and can forget, a unit-conversion step where a tenfold error becomes a tenfold overdose, and a target dose the evidence says probably does less anyway. None of this has been tested in a clinical trial, all of it is off-label, and the product is grey-market. If you're trying to understand how people do this, that's what these tutorials are really asking of you. If you're considering doing it, treat the math as the easy part and the risk as the real story — and talk to a qualified clinician first.

For the related mechanics and risks, see how many units is a microdose in an Ozempic or Wegovy pen, the microdosing tirzepatide dose chart, and the safety review is compounded / microdosed GLP-1 safe. To see how providers compare on price and oversight, we rank them on our GLP-1 microdose rankings hub.